Mode
Text Size
Log in / Sign up
N/A N=109 Randomized Double-blind Treatment

Multifocal High ADD Contact Lens Proof of Concept Trial

Presbyopia

Enrolled (actual)
109
Serious AEs
0.0%
Results posted
Aug 2015
Primary outcome: Primary: High Contrast Visual Acuity (HCVA) Near Monocular — 0.18; 0.32 logMAR

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Lotrafilcon B multifocal contact lenses (new) (Device); Lotrafilcon B multifocal contact lenses (Device)
Age
Adult, Older Adult · 50+ yrs
Sex
All
Sponsor
Alcon Research
Primary completion
Jul 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
High Contrast Visual Acuity (HCVA) Near Monocular
0.18; 0.32
SECONDARY
HCVA Distance Monocular
0.11; 0.06
SECONDARY
HCVA Intermediate Monocular
0.04; 0.02
SECONDARY
Low Contrast Visual Acuity (LCVA) Distance Monocular
0.44; 0.39

Summary

The purpose of this study is to evaluate the visual performance of a new multifocal High ADD contact lens compared to the currently-marketed AIR OPTIX® AQUA MULTIFOCAL (AOAMF) High ADD Contact Lens.

Eligibility Criteria

Inclusion Criteria

  • Must sign an Informed Consent document;
  • Presbyopic and require at least 2.25 diopters (D) spectacle ADD power;
  • Current or previous soft contact lens wearer;
  • Not able to achieve monocular near visual acuity (VA) 0.2 logarithm of the Minimum Angle of Resolution (logMAR) [Early Treatment of Diabetic Retinopathy Study (ETDRS)] or better in each eye with AIR OPTIX® AQUA Multifocal (AOAMF) High ADD Contact Lenses;
  • Willing and able to wear multifocal contact lenses in both eyes within the available range of powers for this trial;
  • Manifest cylinder less than or equal to 1.00 D;
  • Able to achieve best corrected visual acuity (BCVA) of 20/25 or better in each eye at distance (as determined by manifest refraction);
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria

  • Any anterior segment infection, inflammation, disease, or abnormality that contraindicates contact lens wear within 6 months prior to enrollment, as determined by the investigator;
  • Any use of systemic or ocular medications for which contact lens wear could be contraindicated, as determined by the investigator; or any use of topical ocular medications that would require instillation during contact lens wear;
  • Any history of herpetic keratitis;
  • History of corneal or refractive surgery, irregular cornea or unilateral pseudophakia;
  • Biomicroscopy findings (except for corneal vascularization) that are moderate (Grade 3) or severe (Grade 4);
  • Corneal vascularization that is mild (Grade 2) or higher;
  • A pathologically dry eye that precludes contact lens wear;
  • Monocular (only 1 eye with functional vision);
  • Anisometropia ≥ 1.50 D (contact lens distance prescription);
  • Clinically significant (> 1 millimeter) anisocoria;
  • History of intolerance or hypersensitivity to any component of the investigational products;
  • Concurrent participation in a contact lens or contact lens care product clinical trial within the previous 30 days;
  • Eye injury or ocular or intra-ocular surgery within 6 months prior to enrollment;
  • Any ocular or systemic medical condition that may, in the opinion of the Investigator, preclude safe administration of the study lenses or affect the results of this study;
  • Other protocol-defined exclusion criteria may apply.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02117544). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search